We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: UCO, RUSL, NEED, CURE and YINN
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 7, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: (UCO - Free Report) , , , (CURE - Free Report) and (YINN - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Leveraged ETFs of the Last Week
Despite a stupendous oil rally, last week was quite downbeat for the broader market. The S&P 500 (down 5.6%), Dow Jones (down 6.2%) and Nasdaq (down 5%) were all in the negative territory. Rise in coronavirus cases globally was the primary reason for the declines. Against this backdrop, we highlight a few leveraged ETFs that gained in the week.
Oil — ProShares Ultra Bloomberg Crude Oil — Up 64.44%
After being battered by the global price war instigated by the Saudi Arabia and Russia, oil prices bounced back on Apr 2 with more than a 25% rally (a record single-day jump) on Trump’s tweets that indicate chances of an end to the price war. Thanks to such a monumental one-day rise, the entire energy sector picked up last week (read: Will Oil Continue Riding the Trump Mojo? ETFs in Focus).
Russia — Direxion Daily Russia Bull 2X Shares — Up 19.53%
Russia, the energy-rich nation, has probably seen its stocks rally last week on hopes of a recovery in oil price. The underlying MVIS Russia Index is a rules-based index, intended to represent the overall performance of publically-traded companies that are domiciled and primarily listed on an exchange in Russia or that are not Russian companies, but nonetheless generate at least 50% of their revenues in Russia.
It is a non-cyclical sector and is likely to be less hammered by any market crash. The sector emerged as a true safe haven amid the latest crisis as people on self-quarantine need daily essentials at the least (read: Investors Love These ETF Areas Amid Virus-Led Bear Market).
With the coronavirus outbreak spreading rapidly, the entire world is striving to come up with a vaccine or medicine. Notably, the mRNA vaccine against COVID-19 was made in 63 days by Moderna. The first participant in the Phase 1 trial received a dose of the vaccine candidate on Mar 16. However, the Phase 1 clinical trial is expected to conclude on Jun 1, 2021.Johnson & Johnson also announced that it selected a lead vaccine candidate for COVID-19 on Mar 30. Then there is experimental COVID-19 drug Remdesivir from Gilead. Also, a large increase in demand for testing kits is being observed (read: Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development).
China — Direxion Daily FTSE China Bull 3X Shares — Up 4.6%
Despite being the epicenter of the pandemic, China stocks beat Wall Street in Q1 surprisingly, having lost only 11% in dollar terms. Notably, the S&P 500 and the Dow Jones lost about 20% and 23.2%, respectively, in Q1. China's central bank unexpectedly cut the key rate by 20 basis points at March-end, the largest in nearly five years, in order to infuse $10 billion into the money markets. On Apr 3, China's central bank cut the amount of cash that small banks must hold as reserves, releasing around 400 billion yuan ($56.38 billion) in liquidity (read: These China ETFs Hardly Felt Any Coronavirus Pain in Q1).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: UCO, RUSL, NEED, CURE and YINN
For Immediate Release
Chicago, IL – April 7, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: (UCO - Free Report) , , , (CURE - Free Report) and (YINN - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Leveraged ETFs of the Last Week
Despite a stupendous oil rally, last week was quite downbeat for the broader market. The S&P 500 (down 5.6%), Dow Jones (down 6.2%) and Nasdaq (down 5%) were all in the negative territory. Rise in coronavirus cases globally was the primary reason for the declines. Against this backdrop, we highlight a few leveraged ETFs that gained in the week.
Oil — ProShares Ultra Bloomberg Crude Oil — Up 64.44%
After being battered by the global price war instigated by the Saudi Arabia and Russia, oil prices bounced back on Apr 2 with more than a 25% rally (a record single-day jump) on Trump’s tweets that indicate chances of an end to the price war. Thanks to such a monumental one-day rise, the entire energy sector picked up last week (read: Will Oil Continue Riding the Trump Mojo? ETFs in Focus).
Russia — Direxion Daily Russia Bull 2X Shares — Up 19.53%
Russia, the energy-rich nation, has probably seen its stocks rally last week on hopes of a recovery in oil price. The underlying MVIS Russia Index is a rules-based index, intended to represent the overall performance of publically-traded companies that are domiciled and primarily listed on an exchange in Russia or that are not Russian companies, but nonetheless generate at least 50% of their revenues in Russia.
Consumer Staples — Direxion Daily Consumer Staples Bull 3XShrs — Up 8.2%
It is a non-cyclical sector and is likely to be less hammered by any market crash. The sector emerged as a true safe haven amid the latest crisis as people on self-quarantine need daily essentials at the least (read: Investors Love These ETF Areas Amid Virus-Led Bear Market).
Healthcare — Direxion Daily Healthcare Bull 3X Shares — Up 4.8%
With the coronavirus outbreak spreading rapidly, the entire world is striving to come up with a vaccine or medicine. Notably, the mRNA vaccine against COVID-19 was made in 63 days by Moderna. The first participant in the Phase 1 trial received a dose of the vaccine candidate on Mar 16. However, the Phase 1 clinical trial is expected to conclude on Jun 1, 2021.Johnson & Johnson also announced that it selected a lead vaccine candidate for COVID-19 on Mar 30. Then there is experimental COVID-19 drug Remdesivir from Gilead. Also, a large increase in demand for testing kits is being observed (read: Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development).
China — Direxion Daily FTSE China Bull 3X Shares — Up 4.6%
Despite being the epicenter of the pandemic, China stocks beat Wall Street in Q1 surprisingly, having lost only 11% in dollar terms. Notably, the S&P 500 and the Dow Jones lost about 20% and 23.2%, respectively, in Q1. China's central bank unexpectedly cut the key rate by 20 basis points at March-end, the largest in nearly five years, in order to infuse $10 billion into the money markets. On Apr 3, China's central bank cut the amount of cash that small banks must hold as reserves, releasing around 400 billion yuan ($56.38 billion) in liquidity (read: These China ETFs Hardly Felt Any Coronavirus Pain in Q1).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.